ORASURE TECHNOLOGIES INC — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
OraSure reported Q2 2026 net revenues of $30.6 million (down 2% YoY but up 9.7% sequentially), with GAAP operating income of $5.4 million vs. operating loss of $18.0 million in Q2 2025. The improvement was primarily driven by a $22.6 million reduction in acquisition-related contingent consideration liability due to updated FDA submission plans for the CT/NG test. The company received FDA clearance for Colli-Pee Dx STI collection kit and Emergency Use Authorization for OraQuick Ebola 2.0 test. Cash position: $160.6 million; share repurchases of $22 million (7.7M shares, 10%+ of outstanding); Q3 2026 guidance: $29.5M–$32.5M revenue.
Why this rating
Contingent liability reduction is non-cash accounting gain; core revenue flat YoY; FDA approvals are positive but early-stage; cash burn ($23.8M operating cash outflow H1 2026) relative to $160.6M balance sheet (73% of market cap) signals continued losses.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.